Compare LIVE & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | ALXO |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3M | 79.7M |
| IPO Year | N/A | 2020 |
| Metric | LIVE | ALXO |
|---|---|---|
| Price | $15.20 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 9.5K | ★ 268.8K |
| Earning Date | 12-11-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.93 | N/A |
| Revenue | ★ $444,944,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $0.40 |
| 52 Week High | $25.88 | $2.27 |
| Indicator | LIVE | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 69.30 | 54.56 |
| Support Level | $9.05 | $1.29 |
| Resistance Level | $12.49 | $1.57 |
| Average True Range (ATR) | 1.43 | 0.12 |
| MACD | 0.73 | 0.02 |
| Stochastic Oscillator | 74.22 | 80.00 |
Live Ventures Inc is a holding company for diversified businesses. It is focused on acquiring and operating profitable companies in various industries. The company operates in the business segments of Retail Entertainment which includes direct sales of entertainment and appliance products and services, Flooring Manufacturing, Steel Manufacturing, which includes the sale of steel plates, ground flat stock, and drill rods, and Corporate and Other. It derives key revenue from the Flooring Manufacturing segment which includes the manufacturing of carpets and rugs, yarn products, as well as a reseller of hard surface flooring products. Geographically the activities are carried out throughout the United States.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.